Nano Dimension and Infinite Epigenetics Provide Additional Information Regarding Proposed Business Combination

Nano Dimension (NNDM) and Infinite Epigenetics have released clarifying statements regarding their proposed business combination, addressing stakeholder questions and responding to correspondence from Murchinson Ltd. The announcement appears designed to reinforce confidence in the transaction structure and articulate the strategic rationale underpinning the merger.

The companies emphasized Infinite's business model and market opportunity in their communication, suggesting investor concerns centered on commercial viability and addressable market size. By providing additional color on capital allocation plans, management is attempting to demonstrate financial discipline and clear use-of-proceeds methodology—critical factors in SPAC-adjacent transactions where governance and execution risk remain elevated.

The response to Murchinson Ltd.'s letter indicates shareholder activism or scrutiny around deal terms, potentially including valuation, dilution, or post-combination management structure. This type of pre-deal pushback is common in blank-check company combinations and does not inherently signal deal termination risk, but rather reflects due diligence in progress.

Sector implication: Biotech/precision medicine convergence (epigenetics) combined with advanced manufacturing (3D printing via Nano Dimension) creates cross-sector exposure. The announcement's neutral tone and responsive posture suggest management confidence but limited catalysts for near-term equity appreciation absent additional fundamental disclosures or deal milestone announcements.